- Home
- MGLD vs CMMB Comparison
MGLD vs CMMB Comparison
Compare MGLD & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- CMMB
- Stock Information
- Founded
- MGLD 1996
- CMMB 2004
- Country
- MGLD United States
- CMMB Israel
- Employees
- MGLD N/A
- CMMB N/A
- Industry
- MGLD Finance/Investors Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- MGLD Finance
- CMMB Health Care
- Exchange
- MGLD Nasdaq
- CMMB Nasdaq
- Market Cap
- MGLD 45.4M
- CMMB 37.3M
- IPO Year
- MGLD N/A
- CMMB N/A
- Fundamental
- Price
- MGLD $0.97
- CMMB $1.71
- Analyst Decision
- MGLD
- CMMB Strong Buy
- Analyst Count
- MGLD 0
- CMMB 2
- Target Price
- MGLD N/A
- CMMB $9.00
- AVG Volume (30 Days)
- MGLD 68.0K
- CMMB 830.9K
- Earning Date
- MGLD 03-04-2025
- CMMB 03-06-2025
- Dividend Yield
- MGLD N/A
- CMMB N/A
- EPS Growth
- MGLD N/A
- CMMB N/A
- EPS
- MGLD N/A
- CMMB N/A
- Revenue
- MGLD $32,057,000.00
- CMMB N/A
- Revenue This Year
- MGLD N/A
- CMMB N/A
- Revenue Next Year
- MGLD N/A
- CMMB N/A
- P/E Ratio
- MGLD N/A
- CMMB N/A
- Revenue Growth
- MGLD N/A
- CMMB N/A
- 52 Week Low
- MGLD $0.95
- CMMB $0.58
- 52 Week High
- MGLD $2.10
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- MGLD 33.18
- CMMB 32.89
- Support Level
- MGLD $1.00
- CMMB $1.66
- Resistance Level
- MGLD $1.16
- CMMB $2.06
- Average True Range (ATR)
- MGLD 0.07
- CMMB 0.16
- MACD
- MGLD 0.01
- CMMB -0.04
- Stochastic Oscillator
- MGLD 0.37
- CMMB 9.43
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.